SynthesisThoracic cancer2018
Location of stage I-III non-small cell lung cancer and survival rate: Systematic review and meta-analysis.
Synthesis in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Predicting lung cancer survival with attention-based CT slices combination.Health information science and systems · 2026Article
- Association between the presence of EGFR or ALK mutations and the location of primary non-small cell lung cancer, as well as metabolic activity observed onOncology letters · 2026Article
- Application of artificial intelligence-assisted education for postoperative pulmonary rehabilitation: a hybrid model of AI and nurse-driven support.Journal of cardiothoracic surgery · 2026Article
- Efficacy and Safety of Different Types of Traditional Chinese Medicine Preparations Combined with EGFR-TKIs for Patients with Non-Small Cell Lung Cancer: A Network Meta-analysis.Chinese journal of integrative medicine · 2026Article
- Artificial intelligence-assisted machine learning models for predicting lung cancer survival.Asia-Pacific journal of oncology nursing · 2025Article
- Development and Validation of a Machine Learning-Based Predictive Model for Postoperative Frailty in Patients with Non-Small Cell Lung Cancer and Its Relation to Early Recovery.Annals of surgical oncology · 2025Article
- Curative intent therapy of stage I-III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms.Journal of thoracic disease · 2025Article
- An explainable AI approach to surgical and radiotherapy interventions for optimized treatment decision-making in early-stage non-small cell lung cancer.Translational lung cancer research · 2025Article
- Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer.Medical sciences (Basel, Switzerland) · 2025Review
- Middle lobe tumors and lymphovascular invasion as independent predictors of recurrence-free survival in stage I NSCLC.BMC pulmonary medicine · 2025Article
- Combined inflammatory-lipid index and tumor markers for predicting the spatial localization of lesions in early-stage non-small cell lung cancer.Frontiers in oncology · 2025Article
- Development of a nomogram for overall survival prediction in primary upper lobe lung cancer patients: A SEER population-based analysis.PloS one · 2025Article
- Article
- The Cancer Spectrum Theory.Cancer discovery · 2024Article
- Distribution and characteristics of malignant tumours by lung lobe.BMC pulmonary medicine · 2024Article
- Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms.Chinese herbal medicines · 2023Review
- [Development and Validation of A Prognostic Nomogram to Guide Decision-making in Lung Large Cell Neuroendocrine Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- An eleven-gene risk model associated with lymph node metastasis predicts overall survival in lung adenocarcinoma.Scientific reports · 2023Article
- Review
- Novel nutritional indicator as predictors among subtypes of lung cancer in diagnosis.Frontiers in nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between the location of non-small cell lung cancer (NSCLC) and prognosis is a debated issue. Some studies have provided evidence of better prognosis of upper lobe tumors than lower to middle lobe tumors, while other studies have reported contrasting conclusions. The aim of this study was to further assess this association through a systematic review and meta-analysis.
methodsMedline, Embase, and the Cochrane Central Register of Controlled Trials were searched up to 27 January 2017. Patients pathologically diagnosed with stage I-III NSCLC with three or five-year survival data were included. The main meta-analysis compared differences in survival rates according to the primary tumor location using the Mantel-Haenszel method with a random effect model. Sensitivity analysis was conducted according to lymph node metastasis, tumor node metastasis stage, staging method, and treatment modality.
resultsTen clinical studies and 35 570 patients were recruited. Patients with tumors in the upper lobes had a higher rate of five-year survival compared to those with tumors in non-upper lobes (odds ratio [OR] 1.31, 95% confidence interval [CI] 1.15-1.49). Similarly, the three-year survival rate was high in patients with tumors in the upper lobes (OR 1.99, 95% CI 1.02-3.86) and low in those with lower lobe tumors (OR 0.31, 95% CI 0.12-0.77).
conclusionsStage I-III NSCLC located in the upper lobes showed higher five-year survival rates compared to other tumor locations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.